Future Research Goals in Immunotherapy

Tyler W Hulett; Bernard A Fox; David J Messenheimer; Sebastian Marwitz; Tarsem Moudgil; Michael E Afentoulis; Keith W Wegman; Carmen Ballesteros-Merino; Shawn M Jensen

doi:10.1016/j.soc.2019.02.006

Future Research Goals in Immunotherapy

Surg Oncol Clin N Am. 2019 Jul;28(3):505-518. doi: 10.1016/j.soc.2019.02.006. Epub 2019 Apr 12.

Authors

Tyler W Hulett¹, Bernard A Fox², David J Messenheimer³, Sebastian Marwitz¹, Tarsem Moudgil¹, Michael E Afentoulis¹, Keith W Wegman¹, Carmen Ballesteros-Merino¹, Shawn M Jensen¹

Affiliations

¹ Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA.
² Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA; Oregon Health & Science University, Portland, OR, USA; UbiVac, Portland, OR, USA. Electronic address: Bernard.Fox@Providence.org.
³ Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877-0368, USA.

PMID: 31079803
DOI: 10.1016/j.soc.2019.02.006

Abstract

In our opinion the most urgent needs to improve patient outcomes are: 1) a deeper ability to measure cancer immunobiology, and 2) increased availability of agents that, coupled with predictive biomarkers, will be used to tailor anti-cancer immunity. Tailoring effective immunotherapy will entail combinations of immunotherapeutics that augment priming of anti-cancer immunity, boost expansion of effector and memory cells of the T, B and NK lineage, amplify innate immunity and relieve checkpoint inhibition. Alternatives to inducing adaptive immunity to cancer include synthetic immunology that incorporate bi-specifics that target T cells to cancer or adoptive immunotherapy with gene-modified immune cells.

Keywords: Biomarkers; Cancer vaccines; Combination immunotherapy; Immunoprofiling; Seromics; T-cell agonists.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Cancer Vaccines / therapeutic use*
Cell- and Tissue-Based Therapy / methods*
Combined Modality Therapy
Humans
Immunotherapy / methods*
Neoplasms / immunology
Neoplasms / therapy*

Substances

Antibodies, Monoclonal
Cancer Vaccines